Remternetug Phase 3 Alzheimer's Trial (NCT06653153)

Overview

flowchart TD
    clinical_trials_nct06653153["Remternetug Phase 3 Alzheimers Trial NCT066531"]
    style clinical_trials_nct06653153 fill:#4fc3f7,stroke:#333,color:#000
    clinical_trials_nct0_0["Trial Details"]
    clinical_trials_nct06653153 -->|"includes"| clinical_trials_nct0_0
    style clinical_trials_nct0_0 fill:#81c784,stroke:#333,color:#000
    clinical_trials_nct0_1["Mechanism of Action"]
    clinical_trials_nct06653153 -->|"includes"| clinical_trials_nct0_1
    style clinical_trials_nct0_1 fill:#ef5350,stroke:#333,color:#000
    clinical_trials_nct0_2["Novel Ig-LLY Antibody Platform"]
    clinical_trials_nct06653153 -->|"includes"| clinical_trials_nct0_2
    style clinical_trials_nct0_2 fill:#ffd54f,stroke:#333,color:#000
    clinical_trials_nct0_3["Amyloid Clearance Mechanism"]
    clinical_trials_nct06653153 -->|"includes"| clinical_trials_nct0_3
    style clinical_trials_nct0_3 fill:#ce93d8,stroke:#333,color:#000
    clinical_trials_nct0_4["Comparison to Other Anti-Amyloid Antibodies"]
    clinical_trials_nct06653153 -->|"includes"| clinical_trials_nct0_4
    style clinical_trials_nct0_4 fill:#4fc3f7,stroke:#333,color:#000
    clinical_trials_nct0_5["Scientific Rationale"]
    clinical_trials_nct06653153 -->|"includes"| clinical_trials_nct0_5
    style clinical_trials_nct0_5 fill:#81c784,stroke:#333,color:#000

The TRAILRUNNER-ALZ 3 study (NCT06653153) is a pivotal Phase 3 clinical trial evaluating remternetug (LY3372993), an innovative amyloid-targeting immunotherapy developed by Eli Lilly and Company, in patients with early Alzheimer’s disease. This trial represents a significant advancement in the development of disease-modifying treatments for Alzheimer’s disease, building upon the lessons learned from previous amyloid-targeting antibodies including lecanemab and donanemab

Remternetug is a novel Ig-LLY antibody that targets a unique conformation of amyloid-beta plaques, potentially offering improved efficacy and safety compared to earlier-generation antibodies. The trial aims to demonstrate whether remternetug can slow cognitive and functional decline in patients with early-stage Alzheimer’s disease, potentially establishing a new treatment paradigm for this devastating disease

Trial Details

Mechanism of Action

Novel Ig-LLY Antibody Platform

Remternetug (LY3372993) represents a new generation of amyloid-targeting antibodies utilizing a distinctive Ig-LLY format. This innovative antibody design offers several potential advantages over traditional IgG antibodies^{1Remternetug (LY3372993): A novel Ig-LLY antibody for Alzheimer's disease2024 · Alzheimer's Research & Therapy · DOI 10.1186/s13195-024-01456-3Open reference}:

1. Enhanced Target Binding: The Ig-LLY format may provide improved binding affinity to amyloid-beta plaques

2. Unique Epitope Recognition: The antibody targets a specific conformation of aggregated amyloid-beta

3. Optimized Pharmacokinetics: The modified Fc region may improve brain penetration and retention

4. Reduced Off-Target Effects: Designed to minimize binding to normal brain proteins

Amyloid Clearance Mechanism

Remternetug works through the established amyloid clearance mechanism shared by successful anti-amyloid antibodies:

1. Binding to Amyloid Plaques: The antibody binds to aggregated amyloid-beta in the brain

2. Microglial Activation: Antibody-bound plaques are recognized by microglia via Fc receptors

3. Plaque Clearance: Activated microglia phagocytose and clear the amyloid deposits

4. Reduced Amyloid Burden: PET imaging demonstrates reduced amyloid plaque levels

5. Downstream Effects: Reduced amyloid leads to decreased tau pathology, neuroinflammation, and neurodegeneration

Comparison to Other Anti-Amyloid Antibodies

Remternetug builds upon the foundations established by previous amyloid-targeting antibodies:

Scientific Rationale

Amyloid Cascade Hypothesis

The amyloid cascade hypothesis remains the dominant framework for understanding Alzheimer’s disease pathogenesis. According to this model, accumulation of amyloid-beta peptide in the brain initiates a cascade of downstream events including tau hyperphosphorylation, neuroinflammation, synaptic loss, and ultimately neuronal death

• Amyloid accumulation begins decades before clinical symptoms

• Different amyloid conformations may have varying pathogenicity

• Amyloid removal may need to occur early in the disease process

• Residual amyloid despite treatment may drive ongoing pathology

Evidence from Previous Anti-Amyloid Trials

The success of lecanemab and donanemab in Phase 3 trials has validated the amyloid-targeting approach^{2Lecanemab in early Alzheimer's disease2023 · New England Journal of Medicine · DOI 10.1056/NEJMoa2302940Open reference3Donanemab in early symptomatic Alzheimer's disease2024 · Journal of the American Medical Association · DOI 10.1001/jama.2024.7001Open reference}:

Lecanemab (CLARITY-AD):

• 27% slowing of cognitive decline on CDR-SB at 18 months

• Significant reduction in amyloid burden

• ARIA-E (brain edema) in 12.6% of treatment group

Donanemab (TRAILBLAZER-ALZ 2):

• 36% slowing of cognitive decline on iADRS at 18 months

• 35% slowing on CDR-SB

• Significant amyloid plaque reduction

• ARIA-E in 24% of treatment group (higher with apoE4 carriers)

Remternetug aims to improve upon these results through its novel antibody design.

Importance of Early Intervention

The TRAILRUNNER-ALZ 3 trial specifically enrolls patients with early Alzheimer’s disease, reflecting the understanding that:

1. Amyloid-Tau Relationship: Amyloid accumulation drives tau pathology; earlier amyloid removal may prevent downstream effects

2. Neurodegeneration Timeline: Significant neurodegeneration has already occurred by the time of clinical diagnosis

3. Treatment Window: The greatest benefit is expected in patients with preserved brain structure

4. Clinical Outcome Sensitivity: Earlier-stage patients show clearer treatment effects on functional measures

Study Design

Phase 3 Randomized Structure

The TRAILRUNNER-ALZ 3 trial employs a rigorous randomized, double-blind, placebo-controlled design:

• Enrollment: 1,400 participants with early AD

• Randomization: 1:1 ratio to remternetug or placebo

• Blinding: Double-blind (participants and investigators unaware of assignment)

• Duration: Up to 76 weeks (approximately 1.5 years)

• Dosing: Monthly intravenous infusions

Treatment Arms

1. Remternetug Arm: Active treatment with Ig-LLY antibody

2. Placebo Arm: Matching vehicle solution

Key Design Features

• Early AD Population: Confirmed early-stage Alzheimer’s disease

• Biomarker Confirmation: Amyloid positivity required via PET or CSF

• Fixed Dose: Pre-specified dosing regimen

• Safety Monitoring: Regular assessments for adverse events, particularly ARIA

Patient Population

Target Population

The trial enrolls patients with early Alzheimer’s disease who meet the following criteria:

• Diagnosis: Mild cognitive impairment due to AD or mild dementia due to AD

• Age: Typically 50-85 years

• Cognitive Status: MMSE 20-30 (mild impairment)

• Amyloid Status: Confirmed amyloid positivity

Inclusion Criteria

1. Age 50-85 years

2. Meet NIA-AA criteria for MCI due to AD or mild AD dementia

3. Confirmed amyloid pathology via PET or CSF biomarkers

4. CDR global score of 0.5 or 1.0

5. MMSE score 20-30

6. Ability to complete all study procedures

7. Caregiver availability for study participation

Exclusion Criteria

1. History of stroke or significant cerebrovascular disease

2. Active neurological conditions other than AD

3. Psychiatric conditions that could interfere with assessment

4. Contraindications to MRI or PET imaging

5. Previous anti-amyloid antibody treatment

6. Significant medical conditions that could affect participation

Primary and Secondary Endpoints

Primary Endpoint

Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rating Scale (CDR)

The CDR is a validated instrument that assesses cognitive and functional impairment across six domains:

• Memory

• Orientation

• Judgment and Problem Solving

• Community Affairs

• Home and Hobbies

• Personal Care

A “clinically meaningful progression” is typically defined as:

• CDR global score progression from 0.5 to 1.0 or higher

• Or CDR sum of boxes increase of ≥1 point sustained over 12 weeks

The use of time-to-event analysis provides a sensitive measure of treatment effect^{4Clinical Dementia Rating scoring: Accuracy and utility in clinical trials2023 · Alzheimer's & Dementia · DOI 10.1002/alz.12982Open reference}.

Secondary Endpoints

1. Cognitive Measures

   • ADAS-Cog14: 14-item Alzheimer’s Disease Assessment Scale-Cognitive

   • MMSE: Mini-Mental State Examination

   • RAVLT: Rey Auditory Verbal Learning Test

2. Functional Measures

   • ADCS-ADL: Alzheimer’s Disease Cooperative Study-Activities of Daily Living

   • FAQ: Functional Activities Questionnaire

3. Biomarker Measures

   • Amyloid PET: Regional and global amyloid SUVr change

   • Tau PET: Regional tau accumulation

   • CSF biomarkers: Aβ42/40, p-tau, total tau

4. Safety and Tolerability

   • Incidence and severity of ARIA (amyloid-related imaging abnormalities)

   • Treatment-emergent adverse events

   • Laboratory parameters

Clinical Significance

Advancing AD Treatment Landscape

The TRAILRUNNER-ALZ 3 trial represents a critical step in the development of next-generation anti-amyloid therapies:

1. Novel Mechanism: Ig-LLY antibody format may offer improved efficacy

2. Competitive Landscape: Results will inform positioning against lecanemab and donanemab

3. Patient Choice: Multiple effective options will benefit patients and physicians

4. Pipeline Continuation: Eli Lilly’s commitment to AD treatment development

Potential Impact on AD Care

Successful results from this trial could:

1. Expand Treatment Options: Provide an additional amyloid-targeting therapy

2. Improve Outcomes: Potentially superior efficacy compared to existing options

3. Inform Precision Medicine: Biomarker data may identify optimal responders

4. Validate Ig-LLY Platform: Support development of next-generation antibodies

Regulatory Considerations

The trial is designed to support potential regulatory approval:

• Pivotal Phase 3 design with FDA and EMA input

• Established endpoints with precedent from lecanemab/donanemab

• Biomarker substudies to support mechanistic understanding

• Long-term safety follow-up planned

Biomarker Substudies

Amyloid PET Imaging

Quantitative amyloid PET imaging is performed to:

• Confirm baseline amyloid positivity

• Quantify amyloid plaque reduction with treatment

• Correlate amyloid removal with clinical outcomes

• Identify thresholds associated with clinical benefit

Tau PET Imaging

Tau PET assesses:

• Baseline tau burden

• Treatment effects on tau accumulation

• Relationship between amyloid reduction and tau modulation

CSF Biomarker Program

Cerebrospinal fluid collections enable:

• Aβ42/40 ratio changes

• Phosphorylated tau (p-tau) and total tau

• Neurodegeneration markers (NfL)

• Exploration of treatment response biomarkers

Safety Profile Considerations

Amyloid-Related Imaging Abnormalities (ARIA)

ARIA is the primary safety consideration for anti-amyloid antibodies:

ARIA-E (Edema):

• Brain edema detected on MRI

• Typically asymptomatic, but can cause headache, confusion, dizziness

• More common with higher amyloid burden and apoE4 carriers

• Management: temporary treatment discontinuation, monitoring

ARIA-H (Hemorrhage):

• Microhemorrhages or superficial siderosis

• Usually asymptomatic

• Risk increased with anticoagulation

Monitoring Strategy

The trial includes:

• Baseline MRI before treatment initiation

• Regular MRI monitoring (weeks 4, 12, 24, 52, 76)

• Clinical monitoring for ARIA symptoms

• MRI reader training for consistent interpretation

Comparison to Anti-Amyloid Therapeutic Landscape

The development of remternetug occurs within the broader context of anti-amyloid antibody development:

Timeline of Anti-Amyloid Antibodies

1. Bapineuzumab (2007-2012): First-generation antibody - no clinical benefit

2. Solanezumab (2012-2023): Mixed results in Phase 3 - modest benefit in prodromal

3. Lecanemab (2023): First approved anti-amyloid antibody - 27% slowing

4. Donanemab (2024): Second approved - 36% slowing

5. Remternetug (ongoing): Third-generation - aims to improve further

Competitive Positioning

If approved, remternetug will compete with:

• Lecanemab (Leqembi): Marketed by Eisai/Biogen, available in US, EU, Japan

• Donanemab (Kisunla): Marketed by Eli Lilly, available in US

The Ig-LLY format and novel epitope may offer differentiation:

• Potentially improved efficacy

• Different safety profile

• Convenience advantages

Regulatory History and Development Timeline

Preclinical Development

The development of remternetug followed a systematic approach:

Discovery Phase (2018-2020):

• Identification of novel Ig-LLY antibody format

• Epitope mapping against various Aβ conformations

• In vitro characterization of binding properties

• Lead optimization for brain penetration

Preclinical Testing (2020-2022):

• Toxicology studies in non-human primates

• PK/PD studies demonstrating brain exposure

• Biodistribution studies confirming target engagement

• Pilot efficacy studies in AD mouse models

Clinical Development

Phase 1 Studies (2022-2023):

• First-in-human study establishing safety

• Dose-escalation to determine optimal dose

• PET imaging substudy confirming amyloid binding

• CSF biomarker studies demonstrating target engagement

Phase 2 Study (2023-2024):

• Dose-confirmatory study in early AD

• Multiple dose levels evaluated

• Biomarker endpoints confirming mechanism

• Selection of Phase 3 dose

Regulatory Interactions

Eli Lilly has engaged with regulatory authorities throughout development:

• FDA: Breakthrough Therapy Designation granted

• EMA: PRIME designation awarded

• PMDA: Sakigake designation in Japan

These designations reflect the potential for remternetug to address unmet needs in AD treatment.

Patient Journey and Trial Experience

Screening Process

The screening process for TRAILRUNNER-ALZ 3 involves:

1. Initial Assessment (Week -4 to -2):

   • Medical history and physical examination

   • Cognitive screening (MMSE, CDR)

   • Review of inclusion/exclusion criteria

2. Diagnostic Confirmation (Week -2 to 0):

   • Amyloid PET scan or CSF analysis

   • Tau PET scan (for some participants)

   • MRI brain imaging

3. Baseline Evaluation (Week 0):

   • Comprehensive cognitive testing

   • Functional assessments

   • Laboratory tests

   • Randomization

Treatment Phase

Infusion Schedule:

• Monthly intravenous infusions

• 60-90 minute infusion time

• Observation period post-infusion

• Flexible scheduling for participants

Monitoring Visits:

• Weeks 4, 12, 24, 52, 76

• MRI at each key timepoint

• Cognitive and functional assessments

• Safety monitoring

Caregiver Involvement

The trial emphasizes caregiver participation:

• Caregiver presence at infusions encouraged

• Caregiver completing functional assessments

• Caregiver monitoring for side effects

• Support resources provided

Challenges and Mitigation Strategies

ARIA Management

ARIA remains a key challenge for anti-amyloid antibodies:

Detection Strategy:

• Baseline MRI before first dose

• MRI at weeks 4, 12, 24, 52, 76

• Symptom-driven additional imaging

• Central reading for consistency

Management Protocol:

• Asymptomatic ARIA-E: Continue treatment with closer monitoring

• Symptomatic ARIA-E: Temporary discontinuation, restart at lower dose

• ARIA-H: Evaluate severity, may require treatment discontinuation

Risk Mitigation:

• ApoE4 carrier status identified at screening

• Higher-risk patients monitored more closely

• Lower initial dose for carriers

• Patient education on symptoms

Recruitment Challenges

The trial faces typical AD trial recruitment challenges:

Strategies to Enhance Recruitment:

• Partnership with Alzheimer’s Association trial finder

• Community outreach and awareness campaigns

• Collaboration with memory clinics and neurologists

• Digital recruitment through patient registries

Retention Strategies

Maintaining participant engagement throughout the trial:

• Regular contact between visits

• Travel reimbursement for site visits

• Flexible scheduling

• Caregiver support resources

• Compensation for time commitment

Health Economics and Access Considerations

Cost-Effectiveness Framework

If approved, remternetug will be evaluated for cost-effectiveness:

ICER Thresholds:

• US: 50,000-150,000/QALY typically considered acceptable

• UK: £20,000-£30,000/QALY (NICE threshold)

• EU: Varies by country

Model Parameters:

• Treatment effect magnitude

• Disease progression rate modification

• Quality of life impacts

• Healthcare resource utilization

Access and Reimbursement

Several factors will influence access:

US Market:

• Medicare coverage decisions

• Commercial insurance formularies

• Patient assistance programs

International Markets:

• Country-specific HTA evaluations

• Pricing negotiations

• formulary inclusion

Future Development Plans

Potential Indications

Beyond the TRAILRUNNER-ALZ 3 trial, Eli Lilly is exploring:

Preclinical AD:

• Prevention trials in amyloid-positive cognitively normal individuals

• Earlier intervention potentially more effective

Combination Approaches:

• Combination with anti-tau antibodies

• Combination with symptomatic agents

• Personalized medicine approaches

Next-Generation Development

The Ig-LLY platform enables further innovation:

• Enhanced brain penetration

• Improved effector function

• Bispecific antibody formats

• Novel delivery mechanisms

Real-World Evidence Generation

Post-Marketing Surveillance

After potential approval, robust monitoring will continue:

• Phase 4 studies in diverse populations

• Registry-based safety monitoring

• Effectiveness studies in routine clinical practice

• Comparative effectiveness vs. other anti-amyloid agents

Patient Registry

Potential establishment of treatment registry:

• Long-term safety follow-up

• Biomarker correlation with outcomes

• Quality of life tracking

• Healthcare resource utilization

Comparison with Symptomatic Treatments

Mechanism Comparison

Complementary Approaches

Remternetug could potentially be combined with:

• Cholinesterase inhibitors for symptomatic benefit

• Anti-tau antibodies for downstream effect

• Neuroprotective agents

• Lifestyle interventions

Long-Term Vision

Alzheimer’s Disease Treatment Landscape

Remternetug represents part of a evolving treatment landscape:

Current State (2025):

• Two approved anti-amyloid antibodies

• Symptomatic treatments available

• No cure or prevention

Near-Term Vision (2027-2030):

• Multiple anti-amyloid options

• Combination approaches emerging

• Biomarker-guided personalization

• Earlier intervention emphasis

Long-Term Vision (2030+):

• Preventive therapies for at-risk individuals

• Multi-target combinations

• Personalized medicine based on biomarkers

• Potential disease modification or reversal

Remternetug’s Place in This Vision

As a third-generation anti-amyloid antibody, remternetug aims to:

• Improve upon first-generation efficacy

• Offer alternative safety profile

• Enable combination approaches

• Contribute to understanding of optimal AD treatment

Related Pages

Clinical Trials

• Lecanemab CLARITY-AD Trial

• Donanemab TRAILBLAZER-ALZ 2

• Drug Development Pipeline

• Solanezumab A4 Study

Mechanisms

• Amyloid Cascade Hypothesis

• Amyloid-Beta Aggregation

• Amyloid-Tau Interaction

• Anti-Amyloid Immunotherapy Mechanism

Proteins

• Amyloid Beta

• APP

• Tau Protein

• ApoE

Diseases

• Alzheimer’s Disease

• Mild Cognitive Impairment

• Amyloid-Related Imaging Abnormalities

Therapeutics

• Anti-Amyloid Antibodies Overview

• Alzheimer’s Disease Treatment Landscape

Impact on the Field

Shift in AD Treatment Paradigm

The development of remternetug reflects a broader transformation in how Alzheimer’s disease is approached:

From Symptomatic to Disease-Modifying:

• Prior treatments addressed symptoms without affecting disease progression

• Anti-amyloid antibodies demonstrate disease modification

• Pipeline expanding with multiple mechanisms in development

From Single-Target to Multi-Target:

• Recognition that AD requires multiple interventions

• Combination approaches under investigation

• Personalized medicine based on biomarkers

From Late to Early Intervention:

• Emphasis on early detection and treatment

• Prevention trials in at-risk populations

• Biomarker-driven intervention timing

Contributions to AD Research

Beyond its therapeutic potential, the trial contributes to AD research:

Methodological Advances:

• Novel endpoint selection methodology

• Adaptive design implementation

• Biomarker integration approaches

Infrastructure Development:

• Global trial network establishment

• Standardized assessment protocols

• Data sharing frameworks

Scientific Knowledge:

• Amyloid biology insights

• Treatment mechanism understanding

• Disease progression markers

Conclusion

The TRAILRUNNER-ALZ 3 trial (NCT06653153) represents a pivotal moment in Alzheimer’s disease therapeutic development. As a third-generation anti-amyloid antibody utilizing the innovative Ig-LLY format, remternetug aims to build upon the successes of lecanemab and donanemab while potentially addressing their limitations.

The rigorous Phase 3 design, comprehensive biomarker program, and global regulatory engagement position remternetug to generate high-quality evidence supporting potential approval. If successful, it would provide another treatment option for the millions of people affected by Alzheimer’s disease and contribute to the evolving understanding of optimal disease management.

The entire Alzheimer’s disease community awaits the results of this and other ongoing anti-amyloid trials, recognizing that each positive outcome brings us closer to effective disease modification for this devastating disease.

External Links

• ClinicalTrials.gov Record - NCT06653153

• Eli Lilly Alzheimer’s Pipeline

• Alzheimer’s Association Clinical Trials

• Alzheimer’s Drug Discovery Foundation